{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:44:06Z","timestamp":1784119446139,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jpba.2024.116647","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T17:51:22Z","timestamp":1734717082000},"page":"116647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Dried blood spot LC-MS\/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling"],"prefix":"10.1016","volume":"255","author":[{"given":"E.","family":"Metscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Meziyerh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.K.O.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.A.R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpba.2024.116647_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jpba.2024.116647_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.jpba.2024.116647_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17512433.2022.2092470","article-title":"Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis","volume":"15","author":"van Gelder","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.jpba.2024.116647_bib4","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/j.1600-6143.2011.03763.x","article-title":"The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation","volume":"11","author":"Busque","year":"2011","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.jpba.2024.116647_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10369","article-title":"The cyclophilin-dependent calcineurin inhibitor voclosporin inhibits SARS-CoV-2 replication in cell culture","volume":"35","author":"Ogando","year":"2022","journal-title":"Transpl. Int."},{"issue":"12","key":"10.1016\/j.jpba.2024.116647_bib6","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.ekir.2023.09.003","article-title":"Voclosporin and the antiviral effect against SARS-CoV-2 in immunocompromised kidney patients","volume":"8","author":"Arends","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.jpba.2024.116647_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1177450","article-title":"Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis","volume":"10","author":"Lindemann","year":"2023","journal-title":"Front. Med."},{"issue":"9621","key":"10.1016\/j.jpba.2024.116647_bib8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(08)60593-0","article-title":"Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jpba.2024.116647_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40262-023-01246-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of voclosporin","volume":"62","author":"Abdel-Kahaar","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2024.116647_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10269","article-title":"Increased tacrolimus exposure in kidney transplant recipients with COVID-19: inflammation-driven downregulation of metabolism as a potential mechanism","volume":"35","author":"Klomp","year":"2022","journal-title":"Transpl. Int."},{"issue":"7","key":"10.1016\/j.jpba.2024.116647_bib11","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1111\/ajt.15943","article-title":"Severe COVID-19 in a renal transplant recipient: a focus on pharmacokinetics","volume":"20","author":"Meziyerh","year":"2020","journal-title":"Am. J. Transpl."},{"issue":"1-2","key":"10.1016\/j.jpba.2024.116647_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2008.08.023","article-title":"Development and validation of a LC\/MS\/MS method for quantifying the next generation calcineurin inhibitor, voclosporin, in human whole blood","volume":"874","author":"Handy","year":"2008","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"5","key":"10.1016\/j.jpba.2024.116647_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jcph.237","article-title":"Population PKPD of voclosporin in renal allograft patients","volume":"54","author":"Mayo","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"10289","key":"10.1016\/j.jpba.2024.116647_bib14","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jpba.2024.116647_bib15","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa025225","article-title":"Screening newborns for inborn errors of metabolism by tandem mass spectrometry","volume":"348","author":"Wilcken","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jpba.2024.116647_bib16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s13318-023-00846-4","article-title":"Dried blood spots-A platform for therapeutic drug monitoring (TDM) and drug\/disease response monitoring (DRM)","volume":"48","author":"Zailani","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jpba.2024.116647_bib17","unstructured":"2017.Shipping guidelines for dried-blood spot specimens.."},{"issue":"12","key":"10.1016\/j.jpba.2024.116647_bib18","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1111\/apa.15264","article-title":"Parents' perspectives on dried blood spot self-sampling from children with epilepsy: a mixed-method study","volume":"109","author":"Linder","year":"2020","journal-title":"Acta Paediatr."},{"issue":"10","key":"10.1016\/j.jpba.2024.116647_bib19","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/AAC.00707-13","article-title":"Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole","volume":"57","author":"van der Elst","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jpba.2024.116647_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00228-022-03417-9","article-title":"Reliability and feasibility of home-based dried blood spot in therapeutic drug monitoring: a systematic review and meta-analysis","volume":"79","author":"Xiaoyong","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.jpba.2024.116647_bib21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"1-2","key":"10.1016\/j.jpba.2024.116647_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/bmc.1572","article-title":"Strategies in quantitative LC-MS\/MS analysis of unstable small molecules in biological matrices","volume":"25","author":"Li","year":"2011","journal-title":"Biomed. Chromatogr."},{"issue":"12","key":"10.1016\/j.jpba.2024.116647_bib23","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/bmc.1450","article-title":"Development of a validated high-throughput LC-ESI-MS method for determination of sirolimus on dried blood spots","volume":"24","author":"Rao","year":"2010","journal-title":"Biomed. Chromatogr."},{"issue":"8","key":"10.1016\/j.jpba.2024.116647_bib24","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.4155\/bio.10.94","article-title":"DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors","volume":"2","author":"D'Arienzo","year":"2010","journal-title":"Bioanalysis"},{"issue":"3","key":"10.1016\/j.jpba.2024.116647_bib25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4155\/bio.11.328","article-title":"Incurred sample reanalysis comparison of dried blood spots and plasma samples on the measurement of lopinavir in clinical samples","volume":"4","author":"Meesters","year":"2012","journal-title":"Bioanalysis"},{"issue":"12","key":"10.1016\/j.jpba.2024.116647_bib26","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1111\/bcp.13755","article-title":"Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device","volume":"84","author":"Zwart","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116647_bib27","unstructured":"ICH. ICH guideline M10 on bioanalytical method validation and study sample analysis. 2022."},{"key":"10.1016\/j.jpba.2024.116647_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123800","article-title":"How does the order of sample analysis influence the matrix effect during LC-MS bioanalysis?","volume":"1227","author":"Gniazdowska","year":"2023","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2024.116647_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.talanta.2013.04.027","article-title":"Fast LC-MS\/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery","volume":"115","author":"Koster","year":"2013","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2024.116647_bib30","first-page":"83","article-title":"Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies","volume":"12","author":"Li","year":"2020","journal-title":"Clin. Pharmacol."},{"issue":"Pt 2","key":"10.1016\/j.jpba.2024.116647_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1107\/S0907444910051905","article-title":"Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin)","volume":"67","author":"Kuglstatter","year":"2011","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"10.1016\/j.jpba.2024.116647_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2147\/OPTH.S11125","article-title":"Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis","volume":"5","author":"Roesel","year":"2011","journal-title":"Clin. Ophthalmol."},{"issue":"5","key":"10.1016\/j.jpba.2024.116647_bib33","first-page":"542","article-title":"ISAtx-247 (Isotechnika\/Roche)","volume":"5","author":"Dumont","year":"2004","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"20","key":"10.1016\/j.jpba.2024.116647_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cells12202440","article-title":"Voclosporin: unique chemistry, pharmacology and toxicity profile, and possible options for implementation into the management of lupus nephritis","volume":"12","author":"Kale","year":"2023","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.jpba.2024.116647_bib35","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.4155\/bio.15.97","article-title":"Hematocrit-independent recovery of immunosuppressants from DBS using heated flow-through desorption","volume":"7","author":"Hempen","year":"2015","journal-title":"Bioanalysis"},{"issue":"4","key":"10.1016\/j.jpba.2024.116647_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther. Drug Monit."},{"issue":"16","key":"10.1016\/j.jpba.2024.116647_bib37","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.4155\/bio.13.156","article-title":"Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions","volume":"5","author":"De Kesel","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2024.116647_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpba.2018.10.010","article-title":"Is the hematocrit still an issue in quantitative dried blood spot analysis?","volume":"163","author":"Velghe","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"24","key":"10.1016\/j.jpba.2024.116647_bib39","doi-asserted-by":"crossref","first-page":"12112","DOI":"10.1021\/acs.analchem.5b03077","article-title":"Dried blood spot technique for the monitoring of ambrisentan, bosentan, sildenafil, and tadalafil in patients with pulmonary arterial hypertension","volume":"87","author":"Enderle","year":"2015","journal-title":"Anal. Chem."},{"issue":"11","key":"10.1016\/j.jpba.2024.116647_bib40","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1111\/bcp.15433","article-title":"Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients","volume":"88","author":"Zwart","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jpba.2024.116647_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1373\/jalm.2016.020289","article-title":"A quantitative method for the measurement of dried blood spot amino acids using ultra-performance liquid chromatography","volume":"1","author":"Bloom","year":"2016","journal-title":"J. Appl. Lab Med."},{"key":"10.1016\/j.jpba.2024.116647_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2022.339889","article-title":"Quantification of immunosuppressants from one 3.2 mm dried blood spot by a novel cold-induced phase separation based LC-MS\/MS method","volume":"1210","author":"Le","year":"2022","journal-title":"Anal. Chim. Acta"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524006897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524006897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:15:54Z","timestamp":1769688954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524006897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"alternative-id":["S0731708524006897"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116647","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dried blood spot LC-MS\/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116647"}}